Affymetrix Acquisition Target eBioscience Posts 9 Percent Revenue Increase, $9.6M Profit in 2011 | GenomeWeb

NEW YORK (GenomeWeb News) – eBioscience recorded $70.9 million in revenues during 2011, leading to a profit of $9.6 million, Affymetrix disclosed in a regulatory filing today.

Waiting to complete its $315 million buy of the San Diego-based flow cytometry and immunoassay reagents firm, Affy today said in a document filed with the US Securities and Exchange Commission that eBioscience's 2011 revenues increased 9 percent over 2010 revenues of $65.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.